gastric bypass and semaglutide Is Oral a Good Fit for Patients After Metabolic Bariatric Surgery? A Biopharmaceutical Mechanistic Perspective Waterfall plot of weight loss

Regular follow-up appointments allow healthcare professionals to assess response objectively through clinical evaluation and full blood count testing, rather than routinely rechecking B12 levels after treatment has begun

Wegovy has a safety advantage for people without gallbladders compared to some alternatives

10.1016/j.cmet.2013.12.015 196

The Phase 2 trial data shows greater weight loss with retatrutide (24.2% vs approximately 15% for semaglutide), though direct head-to-head trials have not been completed

The FDA states that Zepbound activates GLP-1 and GIP hormone receptors to reduce appetite and food intake

Our computationally designed peptide therapeutics may offer a versatile platform for developing and synthesising triple-acting peptide agonists of class B1 GPCRs and could assist in the future design of bioactive therapeutics with improved pharmacodynamics